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Summary The data of 766 patients participating in three German multicentre trials were analysed with regard
to the relationship between baseline characteristics and prognosis in small cell lung cancer (SCLC). The central
aim of this analysis has been to evaluate the role of gender as an independent prognostic factor in SCLC. The
minimum follow-up period for the 652 male and 114 female patients was 36 months. Female patients were
shown to have a higher complete remission rate (35% vs 25%), a superior median survival (ms) (12.1 months
(mo) vs 9.8 mo), and a favourable 2-year survival rate (2ys) (19% vs 8%) to male ones. Various other
prognostic factors have been proved to be significant, such as extent of disease, clinical performance status,
and history of smoking, whereas weight loss prior to chemotherapy and age have been less important factors.
We have been able to ascertain that women's responses were better than those of male patients independent of
any other relevant prognostic variable. Furthermore, results were found to be even more advantageous for
female patients with additional favourable prognostic parameters, i.e. for patients with limited disease (ms
15.2 mo vs 12.0 mo; 2ys 29% vs 9%) or with good performance status (ms 13.4 mo vs 10.4 mo; 2ys 24% vs
7%). A most remarkable observation was made in that the favourable prognostic effect of the female gender
was restricted to patients aged less than 60 years (ms 13.3 mo vs 10.1 mo; 2ys 26% vs 5%), whereas for older
women no advantages over men's results were established (ms 9.3 ml vs 9.1 mo; 2ys 8% vs 7%). A proportion
of 32% of female patients with limited disease aged less than 60 years achieved a 3-year survival rate. We
conclude (a) that sex constitutes a major prognostic factor in SCLC and is especially useful as a predictor for
long-term survival, and (b) that the favourable prognostic value of the female sex is restricted to younger
patients.
Small cell lung cancer treatment during the last decade has
seen no notable alterations, with an average median survival
of one year and a stable proportion of 5% to 10% of
2-year-survivors among large patient populations (Minna et
al., 1985; Havemann et al., 1987a; Wolf et al., 1987;
Havemann et al., 1987b) although efforts have been launched
worldwide in order to increase the activity of chemotherapy
regimens and a significant progress in the understanding of
tumour biology has been made. With regard to achieving
further improvement of survival rates, approaches aiming at
variations in chemotherapy schedules seem to be less promis-
ing. Thus the main challenges in treatment of SCLC will be
found in (a) the creation of completely new treatment
modalities based on experimental studies on tumour biology,
and (b) the introduction of individualised treatment
modalities for subsets of patients with differing prognoses.
For these aims to be achieved, extensive evaluations of prog-
nostic variables in SCLC will have to be made available. Up
until now only two variables out of a variety of patients'
baseline characteristics, namely extent of disease and clinical
performance status, have been identified as consistent factors
with an essential value for survival prognosis (Morstyn et al.,
1984; Livingston et al., 1978; Osterlind et al., 1986; Souhami
et al., 1985; Kalter et al., 1984; Vogelsang et al., 1985; Ihde
et al., 1981; Rawson et al., 1990). Data about the prognostic
value of the patient's sex have been controversial. Several
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authors maintain that the sex of the patient lacks significant
prognostic impact (Souhami et al., 1985; Ihde et al., 1981;
Rawson et al., 1990; Einhorn et al., 1978; Vincent et al.,
1987), whereas others have been able to show a superior
outcome for female patients for subgroups ofpatients at least
(Osterlind et al., 1986; Maurer et al., 1981; Sagman et al.,
1988; Dearing et al., 1988; Spiegelman et al., 1989). Therefore,
the major aim of this investigation has been to analyse the
prognostic value of sex of the patient in a large series of
individuals, and to define its impact on survival prognosis.
Patients and methods
From May, 1981, to December, 1986, a total of 784 patients
with SCLC were accrued by 15 hospitals across Germany
who then participated in three consecutive multicentre ran-
domised trials.
Criteria for eligibility, staging, stratification and reevalua-
tion were the same in all studies and have already been
described (Havemann et al., 1987a; Wolf et al., 1987; Have-
mann et al., 1987b). All studies were to be effectuated as
randomised trials, the schedules of which are given in detail
in Table I.
In study no. I, a comparison was made between the se-
quential CAV therapy and an alternating therapy with three
different drug combinations (EVI/PAV/CMC) (Havemann et
al., 1987a). In study no. II, an ifosfamide/etoposide (IE)
chemotherapy and a cisplatinum/etoposide (PE) chemother-
apy were compared (Wolf et al., 1987). In study no. III, a
fixed cyclic alternating chemotherapy with IE and CAV was
contrasted to a response-orientated alternating chemotherapy
with IE therapy up to the maximum response and a subse-
quent switch to CAV following immediately afterwards
(Havemann et al., 1987b).
In each study, patients with limited disease received chest
irradiation after the chemotherapy had been completed.
Forty-five Gy were given in 23 fractions over 5 weeks. Pro-
phylactic cranial irradiation was administered to all patients
with complete remission. Thirty Gy were given in ten frac-
tions within 2 weeks following the third cycle of chemo-
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Table I Treatment regimens for three consecutive trials
Study I Arm A: cyclosphamide 1000 mg/M2 i.v. on day 1
adriamycin 50mg/M2 i.v. on day 1
vincristine 2mg i.v. on day 1
(8 cycles in 3-week intervals. Non-responders were switched to
the arm B regimen.)
Arm B: etoposide 80 mg/M2 i.v. on days 1-3
vindesine 3 mg/M2 i.v. on days 1
ifosfamide 1500 mg/M2 i.v. on days 1-5
(cycles 1, 3 and 5) alternating with
cisplatinum 90 mg/M2 i.v. on day 1
adriamycin 60mg/M2 i.v. on day 1
vincristine 2 mg i.v. on day 1
(cycles 2, 4 and 6) and followed by
cyclophosphamide 1000 mg/M2 i.v. on days 1 + 22
methotrexate 15 mg/M2 p.o. on days 1,4,8,11
CCNU 100 mg/M2 p.o. on day 1
(Non-responders were switched to CAV.)
Study II Arm A: cisplatinum 80 mg/m2 i.v. on day 1
etoposide 150 mg/m2 i.v. on days 3-5
(6 cycles in 3-week intervals. Non-responders were switched
to CAV.)
Arm B: ifosfamide 1500 mg/m2 i.v. on days 1-5
etoposide 120 mg/M2 i.v. on days 3-5
(6 cycles in 3-week intervals. Non-responders were switched
to CAV.)
Study III Arm A: ifosfamide 1500 mg/M2 i.v. on days 1-5
etoposide 120 mg/M2 i.v. on days 3-5
alternating with
cyclophosphamide 600 mg/M2 i.v. on days 1 + 2
adriamycin 50mg/m2 i.v. on day 1
vincristine 2 mg i.v. on day 1
Arm B: ifosfamide/etoposide therapy up to the maximum
response and subsequently an immediate switch to
cyclo-phosphamide/adriamycin/vincristine
therapy or in the case of complete remission, on the onset of
the same. No maintenance therapy was given to patients who
had achieved complete remission.
Statistical methods
Survival curves were calculated and plotted according to the
Kaplan-Meier method. The statistical comparison of the sur-
vival curves for male and female patients was based on the
log rank test (Peto et al., 1977) with stratification for the two
major prognostic variables, i.e. extent of disease and perfor-
mance status unless stated otherwise.
An attempt of a comparative analysis of the relative
influence of differing prognostic variables has been made by
Cox's Proportional Hazard Model (Cox, 1972). Any analysis
seeking to identify prognostic factors will have to be con-
sidered an exploratory effort, since it is impossible to deter-
mine beforehand all hypotheses that will be examined. Con-
sequently the given P-values have not been corrected in terms
of the effect of multiple testing on the error of the first kind
and should be understood to be merely descriptive. Never-
theless, P-values of less than 0.001 can clearly be interpreted
to signify statistical evidence of the prognostic value of a
variable.
Results
During the recruitment period, a total of 785 patients entered
the three multicentre trials. Nineteen patients had to be
excluded because ofwrong histology (seven patients), surgical
treatment prior to chemotherapy (two patients), or missing
data (ten patients). Patient recruitment was stopped in De-
cember, 1986; the minimum follow-up time accordingly totals
36 months for 766 evaluable patients.
Analysis ofsurvival according to treatment
The three consecutive randomised trials showed very similar
overall treatment results with a median survival of 10.6
months and a 2-year survival for a proportion of 10% of all
patients. Since no significant differences were observed be-
tween the survival curves of each of the three trials, the entire
number of 766 participating patients was then adopted as a
basis for this study, and accordingly a combined analysis of
prognostic factors of the whole group was undertaken.
The role ofsex as an independent prognosticfactor
In each trial, the baseline characteristics age, sex, extent of
disease, performance status, history of smoking, and weight
loss prior to chemotherapy were recorded and subsequently
included into a univariate analysis in order to determine the
prognostic value of each variable. As shown in Table II,
these five characteristics sex, extent of disease, performance
status, history of smoking and weight loss prior to chemo-
therapy, were identified as the main prognostic factors,
whereas age per se had no or only marginal impact on
survival. It is well known that extent of disease and perfor-
mance status are independent prognostic factors, while the
effect of weight loss prior to chemotherapy depends to a
large extent on the correlation with these two factors (cf.
Table III which is explained below). Besides the extent of the
disease and the performance status, the history of smoking
was a third significant prognostic variable. With regard to
the patient's sex, we noticed that female gender had an
impressive advantage. Out of 114 females, 35% achieved a
complete remission, median survival figured 12.1 months and
a 2-year survival was achieved by 19%. On the other hand,
the complete remissiQn rate of the 652 male patients was
25%, median survival was 9.8 months, and a 2-year survival
reached by 8%. The survival curves for both male and female
patients are illustrated in Figure 1.
In concentrating our study in its second stage on the
specific baseline characteristic sex, the next main task was to
analyse whether the female gender constitutes an independent
positive prognostic factor in small cell lung cancer. The
stratified log rank test is well suited to determine the prog-
nostic relevance of a certain characteristic when influences of
a few other well known prognostic parameters can be elim-988 M. WOLF et al.
Table II Relationship of baseline characteristics and survival
Median 2-year
survival survival
No. CR + PR CR (months) rate
Sex
Males 652 66% 25% 9.8 8%
Females 114 69% 35% 12.1 19%
Performance status
Karnofsky 50-70 154 48% 12% 6.2 2%
Karnofsky 80-100 606 72% 30% 10.8 11%
Extent ofdisease
Limited 294 79% 39% 12.5 14%
Extensive 463 59% 18% 8.9 4%
History ofsmoking
Smokers 694 67% 26% 9.9 7%
Non-smokers 63 65% 30% 13.6 17%
Weight loss
Less than 10% 638 69% 29% 10.5 7%
More than 10% 112 54% 13% 8.3 4%
Age
Less than 50 years 156 68% 30% 11.2 8%
50-60 years 312 67% 26% 10.1 9%
More than 60 years 298 64% 24% 9.2 7%
No. = number of patients; CR = complete remission rate;
PR = partial remission rate.
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Figure 1 Survival curve males vs females; ( ) males, n = 652,
median survival: 9.8 months; (---) females, n = 114, median
survival: 12.1 months; P = 0.0001 (stratified log rank test).
inated. Thus the patients were stratified in terms of the two
major prognostic factors upon which all investigators agree,
namely stage of disease and performance status. In our
univariate evaluation, the history of smoking was identified
to be an additional prognostic variable. Initially this variable
had not been included in the stratification design, because its
prognostic relevance is not generally accepted, furthermore
its inclusion would lead to the splitting up of the total
number of patients into small subgroups thus limiting the
reliability of the results. Using the stratified log rank test as
described the survival of men and women differed
significantly as the statistical results confirm with a P-value
of 0.0001. Seeking a confirmation of this result and wishing
to exclude any major influence of smoking, we repeated the
stratified log rank tesk this time including also the history of
smoking in the stratification design. The result found was
nearly indentical with a P-value of 0.0002.
In a third stage of analyses, the prognostic value of the
baseline characteristics was evaluated by using the Cox pro-
portional hazard model. We have taken into account for the
fact that the use of this test is connected with several statis-
tical assumptions which are often ignored. A major problem
is the assumed proportionality of the hazard functions which
may require a re-scaling ofprognostic variables or a stratified
analysis. In the latter case, the stratification variable cannot
be compared to other predictors in terms of its prognostic
value, i.e. as far as our data are concerned, tests for propor-
tionality of the baseline characteristics indicate that the two
variables performance status and sex at least in part do not
fullfil this fundamental requirement for an adequate use of
the Cox model. The impact of the performance status on
survival seems to be more pronounced in the early stages of
the treatment course, whereas sex may be especially impor-
tant for long-term survival. However, in spite of these effects,
we have been able to confirm with the help of the Cox
proportional hazard model that the patient's sex is essentially
relevant for prognosis. The results of this analysis as shown
in Table III indicate that the four variables sex, extent of
disease, performance status and history of smoking constitute
independent prognostic factors, whereas weight loss prior to
chemotherapy and age have been found to be less important.
The regression coefficients illustrate that the factors sex, per-
formance status and history of smoking have had an almost
indentical impact on the hazard function, i.e. on the patient's
risk of dying. This influence was only surpassed by the
impact by which extent of disease has on the prognosis.
Differences in prognosis between male andfemale patients in
important subgroups ofpatients
The aim of the next step of the analysis was to find out,
whether the influence of sex on the prognosis would prove to
be homogeneous within all subgroups of patients. These were
defined according to the extent of the disease, performance
status, history of smoking, weight loss, and age. The results
are summarised in Table IV.
Extent of disease The favourable outcome of female pa-
tients has been proved for those at a limited stage as well as
for those at an extensive stage. Female patients with limited
disease have been found to have a higher CR rate (44% vs
37%), a longer median survival (15.2 months vs 12.0
months), and in particular a higher 2-year survival rate (29%
vs 11%) than males. This difference in survival is statistically
significant (P= 0.0015, log rank test stratified by perfor-
mance status). At an extensive stage, a better prognosis for
women was noted, with a median survival of 10.2 months
and a 2-year survival rate for 9% compared to 8.7 months
and 7% for men. Although this difference seems to be less
impressive, it is still highly statistically significant
(P = 0.0005, log rank test, stratified by performance status).
Performance status Nearly all patients with a low perfor-
mance status graded according to the Karnofsky index to
50-70% had a poor outcome. Although a longer median
survival was achieved by female patients (9.0 months vs 5.9
months), the probability of long-term survival was minimal
in both groups. In contrast to these results, in the subgroup
of patients with a good performance status, a striking
difference in prognosis has been seen. Female patients have
achieved higher response rates (CR rate 39% vs 28%), longer
median survival rates (13.4 months vs 10.4 months), and in
particular a higher 2-year survival rate (24% vs 7%). The
advantage ofthe female sex was statistically significant with a
P-value of 0.0001 (log rank test, stratified by extent of
disease).
History of smoking A superior survival rate for female
patients was notable for smokers as well as for non-smokers.
Non-smoking women had a favourable outcome with a
Table III Results ofthe first analysis by proportional hazard model*
Coefficient Standard error P-value
Sex 0.40 0.11 0.0003
Performance status 0.45 0.10 0.0001
Extent of disease 0.61 0.08 0.0001
History of smoking 0.44 0.15 0.0026
Weight loss 0.19 0.10 0.071
Age 0.11 0.08 0.17
*Thecolumns ofthe table give theestimated regression coefficient for
thecorresponding dichotomous variable in the Coxmodel, its standard
error and the P-value for the test ofthe hypothesis that the coefficient
equals zero.
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Table IV Prognosis of females and males in important subgroups
Complete Median 2-year
No. remission survival survival rate
s Y s C Y
(%) (%) (mo) (mo) (%) (%)
Limited disease 244 52 37 44 12.0 15.2 11 29
Extensive disease 402 63 17 27 8.7 10.2 3 9
Karnofsky 50-70% 128 25 11 20 5.9 9.0 2 0
Karnofsky 80-100% 519 90 28 39 10.4 13.4 7 24
Non-smokers 38 25 32 28 11.0 16.9 10 26
Smokers 608 90 24 37 9.7 11.8 6 17
Weight loss
Less than 10% 547 98 27 34 10.1 12.4 8 18
More than 10% 110 17 10 35 7.9 8.8 3 16
Age
Less than 50 years 131 26 27 46 10.5 15.2 5 18
50-59 years 273 40 23 43 10.0 12.1 6 32
60 years and more 253 49 25 22 9.1 9.3 7 8
median survival of 16.9 months and a 2-year survival rate for
a proportion of 26% compared to a median survival of 11.0
months and a 2-year survival rate of 10% for non-smoking
men. Due to the relatively small number of non-smokers, this
difference failed to achieve statistical significance (P = 0.065,
log rank test, stratified by extent of disease and performance
status).
With smokers, the median survival rate (11.8 months vs 9.7
months) and the 2-year survival rate (17% vs 6%) were
statistically significant favouring women with a P-value of
0.0025 (stratified log rank test). However, the quantity and
duration of smoking slightly differed between male and
female patients. The median cigarette consume for males was
40 packyears (one packyear = 20 cigarettes per day during 1
year) as opposed to 30 packyears for females. So far
it has not been possible to affirm positively whether the
difference in smoking quantity constitutes an additional prog-
nostic variable due to the restricted data available about this
problem.
Weight loss prior to chemotherapy As has been described
before, the impact of weight loss prior to chemotherapy on
survival was small. As expected, a better prognosis for female
patients was found, both for patients with a weight loss of
less than 10% and for patients with a weight loss of more
than 10%. For further details see Table IV.
Age Most noteworthy were the results obtained with regard
to age. Initially, three age categories were established with
ranging from 18-49-year-olds, 50-59-, to 60-75-year-olds.
While the prognosis for men was found to be the same
regardless of age with a median survival of about 10.0
months and a 2-year survival rate for about 6% of the male
patients, a striking difference in survival was seen for female
patients of all three categories. Women aged less than 50
years (median survival 15.2 months, 2-year survival rate
18%) and women aged 50-59 years (median survival 12.1
months, 2-year survival rate 32%) achieved results superior
to those of the older female population (median survival 9.3
months, 2-year survival rate 8%). The comparison of the
survival curves of female and male patients was of statistical
significance for the group of women aged less than 50 years
(P = 0.0057) and for the ages 50-59 (P = 0.0003), whereas
no difference was noted in the 59-plus-group (P = 0.12,
stratified log rank test). The differing 2-year survival rates for
females aged less than 50 years and 50-59 years are most
likely an artefact which is due to the small patient number.
The comparison of the survival curves of these two popula-
tions reveals no difference, whereas both curves are clearly
superior to the survival of female patients older than 59
years. Therefore, the survival difference between younger and
older women can be described in an appropriate way by
using a two-stage classification which divides female patients
into two groups, one including ages less than 60 years and
one 60-plus. The comparison of the survival curves for both
male and female patients in these two age groups are shown
in Figures 2 and 3. Among the patients aged less than 60
years the advantage of the female sex is of high statistical
significance with a P-value of 0.0001. For patients older than
59 years no difference in survival has been seen. In order to
be able to compare the relative importance of the prognostic
factors between males and females, a separate Cox propor-
tional hazard model for prognostic variables in male and
female patients was finally performed. The results of these
analyses are summarised in Table V. The variable age was
shown to have an important impact on the prognosis for
women, but was irrelevant for men. In the female population,
the four baseline characteristics performance status, extent of
disease, history of smoking and age represented major prog-
nostic factors, whereas in the male subpopulation only the
three variables extent of disease, performance status and
history of smoking had a significant impact on survival.
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Figure 2 Survival curve according to age (<60 years); (-)
males, n = 404, median survival: 10.1 months; (---) females,
n = 65, median survival: 13.3 months; P = 0.0001 (stratified log
rank test).
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Figure 3 Survival curve according to age (older than 60 years);
(-) males, n = 249, median survival: 9.1 months; (---) females,
n = 49, median survival: 9.3 months; P = 0.12 (stratified log rank
test).
Illllllllllllilullllllllllllll
. ....T990 M. WOLF et al.
Table V Results of Cox proportional hazard model* for females and males
Coefficient Standard error P-value
Males Performance status 0.43 0.10 0.0001
Extent of disease 0.59 0.09 0.0001
History of smoking 0.37 0.17 0.032
Age 0.06 0.08 0.46
Females Performance status 0.77 0.27 0.0035
Extent of disease 0.59 0.23 0.011
History of smoking 0.60 0.26 0.024
Age 0.49 0.21 0.017
*The columns of the table give the estimated regression coefficient for the
corresponding dictotomous variable in the Cox model, its standard error and the
P-value for the test of the hypothesis that the coefficient equals to zero.
The subgroup of patients with the most favourable out-
come were limited stage female patients aged less than 60
years. They achieved a median survival of 16.4 months and a
3-year survival rate with a proportion of 32% compared to a
median survival of 12.0 months and a 3-year survival rate of
7% for the corresponding male subgroup.
Discussion
In the analysis of the data available about the prognostic
value of baseline characteristics in SCLC, only the two
variables 'extent of disease' and 'clinical performance status'
have consistently constituted important predictors of survival
(Morstyn et al., 1984; Livingston et al., 1978; Osterlind et al.,
1986; Souhami et al., 1985; Kalter et al., 1984; Vogelsang et
al., 1985; Ihde et al., 1981; Rawson et al., 1990). The
influence of the sex on survival has been a matter of con-
troversial discussion. Einhorn et al. (1978) and the two
British analyses from Vincent et al. (1987) and Souhami et al.
(1985) were unable to note any advantage for the female sex.
Recently a large evaluation of prognostic factors in 3,873
patients with SCLC from ten centres of the United Kingdom
reported by Rawson & Peto (1990) also failed to identify sex
as a major prognostic factor. In the analysis of Ihde et al.
(1981) from the NCI in Washington female patients achieved
no superior survial to men either. This analysis, however, was
based on 106 patients only, including 16 female ones. Recent-
ly, an updated evaluation of prognostic factors from the
same institute dealing with 378 cases reported a statistically
significant advantage of female patients over male ones,
especially with regard to long-term survival (Dearing et al.,
1988). Several other large study groups have confirmed this
observation and identified the sex as an independent prog-
nostic factor in SCLC.
Maurer et al. (1981) from the CALGB reported 35% of
2-year survivals among female patients with limited disease
and CR compared to 15% of 2-year survivals among male
patients with limited disease and CR. Median survival, how-
ever, did not differ between men and women in limited stage
nor in extensive stage. The analysis of Osterlind et al. (1986)
from the Finsen Institute Copenhagen identified the female
sex as a statistically significant favourable prognostic feature
in limited stage with regard to 18 months disease-free sur-
vival. Out of 319 male and 124 female patients with limited
stage, an 18 months disease-free survival rate was achieved
by 11.9% of male and 16.9% of female patients. In extensive
stage, no remarkable difference in prognosis was seen. The
evaluation of Sagman et al. (1988) from Toronto also pro-
claimed the female gender to be a statistically significant
predictor of long-term survival in 614 patients with SCLC.
Recently, Spiegelman et al. (1989) from the CALGB pub-
lished an analysis about prognostic factors of 1,521 patients
and stated that the female gender was a significant predictor
of improved survival in limited as well as in extensive stage
patients.
The analysis presented here strongly supports these
findings showing that women live significantly longer than
men. This advantage of female over male patients was more
pronounced in subgroups of patients with additional
favourable prognostic features than in patients with addi-
tional adverse characteristics, and therefore, the sex has been
an especialy important predictor for the probability of long-
term survival.
Although most of the analyses by other investigators about
prognostic variables are in accordance with our results, a few
evaluations failed to demonstrate any difference. There is a
multitude of factors which will have to be looked into when
we are seeking to explain these controversial results and
particular attention should be paid to the following aspects.
(a) First of all some analyses were based on small numbers
of patients. The proportion of female patients in SCLC is
only about 15-20%, so that only large trials including a
sufficient number of women allow statistical evaluation.
(b) The prognostic value of the sex seems to be more
pronounced in subgroups of patients with additional favour-
able prognostic features than in subgroups with adverse char-
acteristics. This suggestion is supported by several of the
aforementioned investigations where advantageous prognoses
were proven for female patients especially in limited stage,
whereas no difference in extensive stage patients was seen
(Osterlind et al., 1986; Vincent et al., 1987).
(c) The prognostic value of the sex seems to be especially
important for long-term survival. This observation comp-
lements the finding that the sex is an important prognostic
factor in subgroups of patients with additional favourable
prognostic features. Only these people live long enough to
demonstrate an impact of a specific variable on late phases of
the survival curve, whereas patients with additional adverse
prognostic factors die early in the course of treatment ir-
respective of the presence of a single favourable parameter.
In accordance with our results, the analysis of the Toronto
group, as well as the Danish group and the CALGB
identified the sex as an important predictor for long-term
survival. On the other hand, Souhami et al. (1990) noticed no
major impact on the survival of SCLC patients in the United
Kingdom.
(d) At this moment in time a sufficient explanation for
these controversial results is not available. Perhaps special
regional factors and environmental stresses or differences in
smoking behaviour have to be regarded as additional prog-
nostic factors. However, the results of our analyses point to
the suggestion that the relationship between the patient's sex
and age has to be considered as an important predictor for
survival. The advantage of female patients seems to be
restricted to younger ones. When analysing our data, we
noticed the striking statistical significance of the advantage of
female patients aged less than 60 years over male ones,
whereas no difference in survival was seen for patients in the
60-plus group.
This relationship of sex and age has not been considered in
any other evaluation. If predominantly older females had
been recruited in these trials, the differences in prognosis
might have been covered. However, in spite of the striking
superiority of the female sex in our data set, we have to
admit that the number of female patients was relatively
small, so that our findings about the relationshiop between
the patient's sex and age will have to be confirmed with the
help of a larger set of patients.SEX AS PREDICTOR FOR SURVIVAL IN SCLC 991
The reasons for the superiority of the female sex are still
not completely known. It is obvious that women have a
better prognosis than men in a large variety of malignant
diseases. In SCLC several aspects have been suggested as
contributors to this advantage. Osterlind et al. (1986) sug-
gested that female patients as opposed to male ones may
receive a rather more aggressive chemotherapy. In their
analysis leukocyte nadirs were lower in women than in men
which is likely to favour this hypothesis. Spiegelman et al.
(1989) also performed such an evaluation but this group
noticed no difference in myelotoxicity, performance of treat-
ment and side effects between male and female patients.
When analysing our own data, we, too, were unable to
confirm the suggestion by Osterlind et al. (1986) leukocyte
nadirs and leukocyte values prior to each cycle of
chemotherapy did not differ between both groups. Further-
more, clinical side effects according to the WHO criteria
occurred in nearly the same frequencies in both, female and
male patients. The performance of treatment was com-
parable, too, with a slightly higher number of cycles of
chemotherapy and irradiation given to men. From these data
we conclude that the advantage of the female sex was not
due to differences in the performance of treatment.
A second aspect which has to be considered is the different
history of smoking of female and male patients. The propor-
tion of non-smokers was higher in women than in men, and
even the smoking women had less tobacco consume than the
smoking men. The history of smoking seems to be a further
independent prognostic variable with favourable impact on
survival for non-smokers. But even when the history of
smoking was included into the multivariate test systems, the
sex still remains an independent prognostic factor. However,
as for the analysis of the relationship of sex and age, we have
to admit that our patient population and especially the
number of female ones and non-smokers are too small for a
definitive evaluation.
As to the observation that the better prognosis of females
was restricted to the younger population we suggested that
sexual hormones may play a role in the regulation of tumour
growth and should thus be taken into consideration as a
possible reason for the advantage of the female gender. On
average, in the age of 45 years estrogen and progesteron
levels begin to decrease and reach the lowest values in the
middle of the 5th decade of life. Therefore, women older
than 55 years have low female sexual hormone levels and
relatively high androgen levels. On the basis of these facts we
suggested that either female sexual hormones like estrogen
and progesteron may have a protective function or male
sexual hormones like androgen may force tumour growth in
SCLC.
In order to test this hypothesis, the influence of sexual
hormones on cell proliferation in permanent human small
cell lung cancer cell lines has been investigated in our
laboratories. Maasberg et al. (1989) found that 8/13 cell lines
had androgen receptors. The application of testosterone re-
sulted in a 3-fold increase of cell proliferation in the cloning
assay, whereas estrogen had no influence on tumour growth.
Subsequently an anti-androgen was added to this test system
and resulted in a complete compensation of the androgen
effects. The stimulation by androgen was confirmed by
thymidine incorporation assay. Using this method, dehydro-
testosterone was clearly more effective than testosterone sug-
gesting that the stimulation of tumour growth is predom-
inantly due to this metabolite. Dehydro-testosterone is built
by the enzyme 5a-reductase at the level of the cell membrane.
5a-reductase activity was detected in nearly all cell lines
indicating that human small cell lung cancer cells are able to
convert testosterone in dehydro-testosterone. These in vitro
experiments showing an enhancement of cell proliferation by
androgens hint that sexual hormones may play a role in the
regulation of tumour growth in SCLC.
This suggestion will need further confirmation in experi-
mental and clinical studies. However, from these results a
new treatment approach in SCLC may be derived which
focuses on the decrease of androgen levels in males by means
of anti-androgens and LH-RH-agonists. We will test this
strategy and hope to establish a new treatment modality
which may overcome the unique results of chemotherapy in
SCLC during the last decade.
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